Jun 24, 2026 08:00PM
Jun 24, 2026 08:00PM
Jun 24, 2026 07:01AM
Jun 24, 2026 07:00AM
Jun 21, 2026 08:00PM
Jun 21, 2026 08:00PM
May 31, 2026 08:00PM 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
May 31, 2026 08:00PM
May 21, 2026 07:49PM
May 21, 2026 07:49PM
May 21, 2026 07:49PM
May 10, 2026 08:00PM
Mar 1, 2026 07:00PM
Jan 26, 2026 07:00PM Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Oct 21, 2025 08:25PM
Sep 18, 2025 12:00AM
Sep 17, 2025 06:30AM
Sep 7, 2025 08:30PM Innovent presents positive phase 2 results for gout drug tigulixostat
Sep 7, 2025 08:30PM
Aug 27, 2025 06:08AM
Aug 24, 2025 08:00PM
Aug 24, 2025 08:00PM
Aug 4, 2025 08:00PM
Aug 4, 2025 08:00PM
Jul 23, 2025 10:36AM Innovent's gastric cancer drug shows promise in Nature Medicine study
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jul 16, 2025 08:00PM
Jun 30, 2025 12:04AM
Jun 15, 2025 08:00PM
Jun 4, 2025 08:23PM
Jun 3, 2025 08:00PM 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced No
Jun 2, 2025 09:00PM
Jun 1, 2025 08:00PM
May 31, 2025 09:39PM
Mar 30, 2025 09:19PM
Mar 26, 2025 06:21AM
Mar 18, 2025 08:57PM
Mar 18, 2025 08:55PM Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
Mar 2, 2025 07:00PM
Feb 16, 2025 07:00PM
Jan 15, 2025 07:00PM
Jan 2, 2025 07:00PM
Dec 20, 2024 07:10AM
Dec 15, 2024 06:57PM
Dec 15, 2024 06:55PM Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China
Dec 8, 2024 07:00PM

324,023 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All